Crystalline versus amorphous content of Lumaxis(TM) analog XP280 using X-ray and electron diffraction methods

Journal of Pharmaceutical Sciences

Volumn 89, Issue 10, 2000, Pages 1237-1242

  Li, Z G ^a   Liang, L ^a   Harlow, R L ^a   Foris, C M ^a   Olson, R E ^a   Sielecki, T M ^a   Liu, J ^a   Vickery, R D ^a   Maurin, M B ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Crystallinity; Electron diffraction; Lumaxis(TM); Roxifiban; Synchrotron diffraction

Indexed keywords

DRUG METABOLITE; ROXIFIBAN; ROXIFIBAN DERIVATIVE; SC 887; UNCLASSIFIED DRUG; XP 280;

ARTICLE; CRYSTALLIZATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG STRUCTURE; ELECTRON DIFFRACTION; SCANNING ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

EID: 0033771845     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200010)89:10<1237::AID-JPS1>3.0.CO;2-4     Document Type: Article

References (9)

1. Generation of polymorphs, hydrates, solvents, and amorphous solids
2. Thermal analysis and calorimetric methods in the characterization of polymorphism and solvates
3. Coherent electron nanodiffraction from clear silver nano particles in a UHV STEM
4. Discovery of an orally active series of isoxazoline glycoprotein Iib/IIIa antagonists
5. Polymorph determination for the GP IIb/IIIa antagonist, roxifiban, using a combination of electron diffraction and synchrotron X-ray powder diffraction techniques